|Articles|September 20, 2021

Encourage Further SGLT2 Inhibitor Treatment for Diabetes, Kidney Disease, Expert Says

New data from the CREDENCE trial shows that the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce hyperkalemia risk in people with type 2 diabetes and chronic kidney disease who are using RAAS inhibitors.

New data from the CREDENCE trial shows the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin may reduce the risk of hyperkalemia in certain patients with type 2 diabetes (T2D) and chronic kidney disease, and an editorial1 published alongside the new results2 suggests the findings call for additional research to learn whether this effect is shared across this ground-breaking class of medication.

Internal server error